CO5261517A1 - Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis - Google Patents

Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis

Info

Publication number
CO5261517A1
CO5261517A1 CO00087459A CO00087459A CO5261517A1 CO 5261517 A1 CO5261517 A1 CO 5261517A1 CO 00087459 A CO00087459 A CO 00087459A CO 00087459 A CO00087459 A CO 00087459A CO 5261517 A1 CO5261517 A1 CO 5261517A1
Authority
CO
Colombia
Prior art keywords
buprenorfine
buprenorphine
nalmefen
naltrexone
naloxone
Prior art date
Application number
CO00087459A
Other languages
English (en)
Inventor
Chapleo Christopher Bourne
Keith Mccormack
Varey Nicolas Calvert
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of CO5261517A1 publication Critical patent/CO5261517A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

una composición analgésica bajo la forma de una unidad de dosificación parenteral o bajo la forma de una unidad de dosificación adecuada para una administración vía la mucosa que comprende una cantidad de buprenorfina que es menor a la dosis clínica requerida para lograr el alivio del dolor y una cantidad de naloxona tal que la relación de peso entre la buprenorfina y la naloxona esta en el rango de entre 12.5 a 1 y 27.5 a 1, o una cantidad de naltrexona o de nalmefen tal que la relación de peso entre la buprenorfina y la naltrexona o el nalmefen esta en el rango de entre 12.5 a 1 y 22.5 a 1, donde la acción analgésica de la buprenorfina se ve potenciada por la baja dosis de naloxona, de naltrexona o de nalmefen.
CO00087459A 1999-11-19 2000-11-17 Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis CO5261517A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14

Publications (1)

Publication Number Publication Date
CO5261517A1 true CO5261517A1 (es) 2003-03-31

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00087459A CO5261517A1 (es) 1999-11-19 2000-11-17 Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis

Country Status (31)

Country Link
US (4) US6995169B2 (es)
EP (1) EP1242087B1 (es)
JP (1) JP4745576B2 (es)
KR (1) KR100726699B1 (es)
CN (1) CN100431543C (es)
AR (1) AR031682A1 (es)
AT (1) ATE262335T1 (es)
AU (1) AU777259B2 (es)
BR (1) BR0015580A (es)
CA (1) CA2392013C (es)
CO (1) CO5261517A1 (es)
CZ (1) CZ303160B6 (es)
DE (1) DE60009346T2 (es)
DK (1) DK1242087T3 (es)
ES (1) ES2214334T3 (es)
GB (1) GB2356348B (es)
HK (1) HK1055389A1 (es)
HU (1) HU229565B1 (es)
IL (2) IL149580A0 (es)
MX (1) MXPA02004978A (es)
NO (1) NO321965B1 (es)
NZ (1) NZ519023A (es)
PL (1) PL199727B1 (es)
PT (1) PT1242087E (es)
RO (1) RO121174B1 (es)
RU (1) RU2255737C2 (es)
SI (1) SI21025B (es)
SK (1) SK286888B6 (es)
TR (1) TR200400653T4 (es)
TW (1) TW550070B (es)
WO (1) WO2001035942A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US7375111B2 (en) 2003-04-29 2008-05-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
LT1765292T (lt) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Nuo piktnaudžiavimo apsaugotos vaistų formos
DK2135603T3 (da) * 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
EP2089010A1 (en) 2006-10-24 2009-08-19 The John Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
JP2010537989A (ja) * 2007-09-03 2010-12-09 ナノセラピューティクス・インコーポレイテッド 難溶性薬物の組成物及び送達方法
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
SG10201510564PA (en) 2010-12-22 2016-01-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
RS62505B1 (sr) 2011-09-19 2021-11-30 Orexo Ab Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
BR112014030282A2 (pt) 2012-06-06 2017-06-27 Orexigen Therapeutics Inc métodos de tratamento de excesso de peso e obesidade
US20150342946A1 (en) 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP2016529328A (ja) * 2013-09-10 2016-09-23 インシス・ファーマ・インコーポレーテッド 舌下ブプレノルフィンスプレー
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
JP6797691B2 (ja) 2014-04-22 2020-12-09 大塚製薬株式会社 ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3166250A1 (en) * 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
AU5956001A (en) * 2000-05-05 2001-11-20 Pain Therapeutics Inc Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists

Also Published As

Publication number Publication date
CN100431543C (zh) 2008-11-12
JP2003514013A (ja) 2003-04-15
SK286888B6 (sk) 2009-07-06
ATE262335T1 (de) 2004-04-15
NO20022330D0 (no) 2002-05-15
JP4745576B2 (ja) 2011-08-10
BR0015580A (pt) 2002-07-09
US20060058333A1 (en) 2006-03-16
WO2001035942A9 (en) 2002-11-28
HK1055389A1 (en) 2004-01-09
AU1529701A (en) 2001-05-30
PT1242087E (pt) 2004-06-30
HUP0203588A3 (en) 2005-01-28
US7402591B2 (en) 2008-07-22
RU2002116361A (ru) 2004-01-27
TW550070B (en) 2003-09-01
CA2392013A1 (en) 2001-05-25
US20060069113A1 (en) 2006-03-30
IL149580A0 (en) 2002-11-10
DE60009346D1 (de) 2004-04-29
ES2214334T3 (es) 2004-09-16
PL355330A1 (en) 2004-04-19
CZ303160B6 (cs) 2012-05-09
CA2392013C (en) 2009-08-11
NO321965B1 (no) 2006-07-31
KR100726699B1 (ko) 2007-06-13
GB2356348B (en) 2002-02-06
CN1413110A (zh) 2003-04-23
SI21025A (sl) 2003-04-30
US20030004178A1 (en) 2003-01-02
WO2001035942A2 (en) 2001-05-25
WO2001035942A3 (en) 2002-06-13
MXPA02004978A (es) 2003-01-28
DE60009346T2 (de) 2005-02-10
HU229565B1 (hu) 2014-02-28
SI21025B (sl) 2008-04-30
GB0028088D0 (en) 2001-01-03
RO121174B1 (ro) 2007-01-30
GB2356348A (en) 2001-05-23
AU777259B2 (en) 2004-10-07
US20060058332A1 (en) 2006-03-16
EP1242087A2 (en) 2002-09-25
KR20020058022A (ko) 2002-07-12
RU2255737C2 (ru) 2005-07-10
NO20022330L (no) 2002-07-04
TR200400653T4 (tr) 2004-04-21
US6995169B2 (en) 2006-02-07
PL199727B1 (pl) 2008-10-31
NZ519023A (en) 2004-11-26
EP1242087B1 (en) 2004-03-24
HUP0203588A2 (hu) 2003-03-28
IL149580A (en) 2007-05-15
DK1242087T3 (da) 2004-07-19
SK8762002A3 (en) 2002-12-03
AR031682A1 (es) 2003-10-01

Similar Documents

Publication Publication Date Title
CO5261517A1 (es) Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
US5665378A (en) Transdermal therapeutic formulation
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
GT200100211AA (es) Compuestros de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos. (patentefraccionaria no. 1 de la solicitud de patente de invencion no. pi-2001-0211.
PE20001396A1 (es) Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
WO2001082914A3 (en) Topical anesthetic/opioid formulations and uses thereof
ES2074513T3 (es) Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo.
ES2091441T3 (es) Composicion farmaceutica.
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
AR012615A1 (es) Tableta de liberacion controlada de drogas administradas por via sublingual o bucal
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
NO20030897D0 (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
EP1444984B1 (en) Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
BR0114100A (pt) Formulações de liberação controlada para administração oral
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
AR030957A1 (es) Composiciones de analgesico y glucosamina

Legal Events

Date Code Title Description
FG Application granted